ALPS Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

ALPS Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8,504	Closed	-$505K	–	1052
2025 Q4	$505K	Buy	8,504 +69	+0.8%	+$3.76K	﹤0.01%	730
2025 Q3	$457K	Buy	8,435 +3,354	+66%	+$192K	﹤0.01%	768
2025 Q2	$279K	Buy	5,081 +62	+1%	+$3.65K	﹤0.01%	951
2025 Q1	$355K	Sell	5,019 -81	-2%	-$5.45K	﹤0.01%	766
2024 Q4	$335K	Hold	5,100	–	–	﹤0.01%	824
2024 Q3	$358K	Buy	+5,100	New	+$426K	﹤0.01%	828
2022 Q1	–	Sell	-4,830	Closed	-$427K	–	842
2021 Q4	$427K	Buy	4,830 +58	+1%	+$4.79K	﹤0.01%	596
2021 Q3	$369K	Buy	+4,772	New	+$377K	﹤0.01%	646
2020 Q3	–	Sell	-2,618	Closed	-$323K	–	828
2020 Q2	$323K	Sell	2,618 -289	-10%	-$28.7K	﹤0.01%	535
2020 Q1	$246K	Buy	+2,907	New	+$250K	﹤0.01%	579

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ALPS Advisors's BMRN Position: Q1 2026 in Review

ALPS Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 8,504 shares — an estimated $505K sold.

ALPS Advisors first reported a position in BMRN in Q1 2020 and held it in 10 quarters. The position peaked at $505K in Q4 2025. 559 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

ALPS Advisors reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
ALPS Advisors sold 8,504 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $505K.
ALPS Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2020 and held it in 10 quarters.
ALPS Advisors's BioMarin Pharmaceuticals position peaked at $505K in Q4 2025.
559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.